Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies

[Display omitted] •Licensing can enhance the immunomodulatory effect of mesenchymal stromal cells.•Apoptotic bodies derived from mesenchymal stromal cells are immunomodulatory.•The efficacy of apoptotic bodies may be related to their uptake. Mesenchymal stromal cells (MSCs) show great potential for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2023-12, Vol.125 (Pt A), p.111096-111096, Article 111096
Hauptverfasser: Wang, Jiemin, Donohoe, Ellen, Canning, Aoife, Moosavizadeh, Seyedmohammad, Buckley, Fiona, Brennan, Meadhbh Á., Ryan, Aideen E., Ritter, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 111096
container_issue Pt A
container_start_page 111096
container_title International immunopharmacology
container_volume 125
creator Wang, Jiemin
Donohoe, Ellen
Canning, Aoife
Moosavizadeh, Seyedmohammad
Buckley, Fiona
Brennan, Meadhbh Á.
Ryan, Aideen E.
Ritter, Thomas
description [Display omitted] •Licensing can enhance the immunomodulatory effect of mesenchymal stromal cells.•Apoptotic bodies derived from mesenchymal stromal cells are immunomodulatory.•The efficacy of apoptotic bodies may be related to their uptake. Mesenchymal stromal cells (MSCs) show great potential for immunomodulatory and anti-inflammatory treatments. Clinical trials have been performed for the treatment of Type 1 diabetes, graft-versus-host disease and organ transplantation, which offer a promise of MSCs as an immunomodulatory therapy. Nevertheless, their unstable efficacy and immunogenicity concerns present challenges to clinical translation. It has emerged that the MSC-derived secretome, which includes secreted proteins, exosomes, apoptotic bodies (ABs) and other macromolecules, may have similar therapeutic effects to parent MSCs. Among all of the components of the MSC-derived secretome, most interest thus far has been garnered by exosomes for their therapeutic potential. However, since MSCs were reported to undergo apoptosis after in vivo transplantation and release ABs, we speculated as to whether ABs have immunomodulatory effects. In this study, cytokine licensing was used to enhance the immunomodulatory potency of MSCs and ABs derived from licensed MSCs in vitro were isolated to explore their immunomodulatory effects as an effective non-viable cell therapy. IFN-γ and IFN-γ/TGF-β1 licensing enhanced the immunomodulatory effect of MSCs on T cell proliferation. Further, TGF-β1 and IFN-γ licensing strengthened the immunomodulatory effect of MSC on reducing the TNF-α and IL-1β expression by M1 macrophage-like THP-1 cells. Additionally, we discovered the immunomodulatory effect mediated by MSC-derived apoptotic bodies. Licensing impacted the uptake of ABs by recipient immune cells and importantly altered their phenotypes. ABs derived from IFN-γ/TGF-β1-licensed apoptotic MSCs significantly inhibited T cell proliferation, induced more regulatory T cells, and maintained immunomodulatory T cells but reduced pro-inflammatory T cells.
doi_str_mv 10.1016/j.intimp.2023.111096
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2881247788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576923014224</els_id><sourcerecordid>2881247788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-22eac0654fbf2625315716142dc405989406cd56242646fbfb75376da7b165503</originalsourceid><addsrcrecordid>eNp9kE1rHSEUhqWkNGnaf1DKLLOZG3X8uptACW0aCGTTrsXRM8TLqBN1Uu6_r5dJu8zGI_q8Hs-D0BeCdwQTcX3Y-Vh9WHYU02FHCMF78Q5dECVVTyTmZ23Phey5FPtz9LGUA8btnJEP6HyQSpK2XCB_H8IaU0hunU1N-dhNa7TVp9ilqZu9hVjAdU9rMLEbU4QumJzTny5AgWifjsHMXak5naqFee4dZP_SImZJS03V2xZzHson9H4yc4HPr_US_f7x_dftz_7h8e7-9ttDbxlWtacUjMWCs2mcqKB8IFwSQRh17Z7v1Z5hYR0XlFHBRINGyQcpnJEjEZzj4RJdbe8uOT2vUKoOvpx-ZiKktWiqFKFMSqUayjbU5lRKhkkv2bf5jppgfZKsD3qTrE-S9Sa5xb6-dljHAO5_6J_VBtxsALQ5XzxkXaxvtsD5DLZql_zbHf4CKJ6Qow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2881247788</pqid></control><display><type>article</type><title>Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wang, Jiemin ; Donohoe, Ellen ; Canning, Aoife ; Moosavizadeh, Seyedmohammad ; Buckley, Fiona ; Brennan, Meadhbh Á. ; Ryan, Aideen E. ; Ritter, Thomas</creator><creatorcontrib>Wang, Jiemin ; Donohoe, Ellen ; Canning, Aoife ; Moosavizadeh, Seyedmohammad ; Buckley, Fiona ; Brennan, Meadhbh Á. ; Ryan, Aideen E. ; Ritter, Thomas</creatorcontrib><description>[Display omitted] •Licensing can enhance the immunomodulatory effect of mesenchymal stromal cells.•Apoptotic bodies derived from mesenchymal stromal cells are immunomodulatory.•The efficacy of apoptotic bodies may be related to their uptake. Mesenchymal stromal cells (MSCs) show great potential for immunomodulatory and anti-inflammatory treatments. Clinical trials have been performed for the treatment of Type 1 diabetes, graft-versus-host disease and organ transplantation, which offer a promise of MSCs as an immunomodulatory therapy. Nevertheless, their unstable efficacy and immunogenicity concerns present challenges to clinical translation. It has emerged that the MSC-derived secretome, which includes secreted proteins, exosomes, apoptotic bodies (ABs) and other macromolecules, may have similar therapeutic effects to parent MSCs. Among all of the components of the MSC-derived secretome, most interest thus far has been garnered by exosomes for their therapeutic potential. However, since MSCs were reported to undergo apoptosis after in vivo transplantation and release ABs, we speculated as to whether ABs have immunomodulatory effects. In this study, cytokine licensing was used to enhance the immunomodulatory potency of MSCs and ABs derived from licensed MSCs in vitro were isolated to explore their immunomodulatory effects as an effective non-viable cell therapy. IFN-γ and IFN-γ/TGF-β1 licensing enhanced the immunomodulatory effect of MSCs on T cell proliferation. Further, TGF-β1 and IFN-γ licensing strengthened the immunomodulatory effect of MSC on reducing the TNF-α and IL-1β expression by M1 macrophage-like THP-1 cells. Additionally, we discovered the immunomodulatory effect mediated by MSC-derived apoptotic bodies. Licensing impacted the uptake of ABs by recipient immune cells and importantly altered their phenotypes. ABs derived from IFN-γ/TGF-β1-licensed apoptotic MSCs significantly inhibited T cell proliferation, induced more regulatory T cells, and maintained immunomodulatory T cells but reduced pro-inflammatory T cells.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2023.111096</identifier><identifier>PMID: 37871378</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Apoptotic body ; Bone Marrow ; Cells, Cultured ; Exosomes - metabolism ; Extracellular vesicle ; Humans ; IFN-γ ; Immunomodulation ; Licensing ; Mesenchymal Stem Cells - metabolism ; Mesenchymal stromal cells ; Potency ; TGF-β1 ; Transforming Growth Factor beta1 - metabolism</subject><ispartof>International immunopharmacology, 2023-12, Vol.125 (Pt A), p.111096-111096, Article 111096</ispartof><rights>2023 The Author(s)</rights><rights>Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-22eac0654fbf2625315716142dc405989406cd56242646fbfb75376da7b165503</citedby><cites>FETCH-LOGICAL-c408t-22eac0654fbf2625315716142dc405989406cd56242646fbfb75376da7b165503</cites><orcidid>0000-0001-6461-8131 ; 0000-0002-5831-6783 ; 0000-0001-7709-8489</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576923014224$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37871378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jiemin</creatorcontrib><creatorcontrib>Donohoe, Ellen</creatorcontrib><creatorcontrib>Canning, Aoife</creatorcontrib><creatorcontrib>Moosavizadeh, Seyedmohammad</creatorcontrib><creatorcontrib>Buckley, Fiona</creatorcontrib><creatorcontrib>Brennan, Meadhbh Á.</creatorcontrib><creatorcontrib>Ryan, Aideen E.</creatorcontrib><creatorcontrib>Ritter, Thomas</creatorcontrib><title>Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>[Display omitted] •Licensing can enhance the immunomodulatory effect of mesenchymal stromal cells.•Apoptotic bodies derived from mesenchymal stromal cells are immunomodulatory.•The efficacy of apoptotic bodies may be related to their uptake. Mesenchymal stromal cells (MSCs) show great potential for immunomodulatory and anti-inflammatory treatments. Clinical trials have been performed for the treatment of Type 1 diabetes, graft-versus-host disease and organ transplantation, which offer a promise of MSCs as an immunomodulatory therapy. Nevertheless, their unstable efficacy and immunogenicity concerns present challenges to clinical translation. It has emerged that the MSC-derived secretome, which includes secreted proteins, exosomes, apoptotic bodies (ABs) and other macromolecules, may have similar therapeutic effects to parent MSCs. Among all of the components of the MSC-derived secretome, most interest thus far has been garnered by exosomes for their therapeutic potential. However, since MSCs were reported to undergo apoptosis after in vivo transplantation and release ABs, we speculated as to whether ABs have immunomodulatory effects. In this study, cytokine licensing was used to enhance the immunomodulatory potency of MSCs and ABs derived from licensed MSCs in vitro were isolated to explore their immunomodulatory effects as an effective non-viable cell therapy. IFN-γ and IFN-γ/TGF-β1 licensing enhanced the immunomodulatory effect of MSCs on T cell proliferation. Further, TGF-β1 and IFN-γ licensing strengthened the immunomodulatory effect of MSC on reducing the TNF-α and IL-1β expression by M1 macrophage-like THP-1 cells. Additionally, we discovered the immunomodulatory effect mediated by MSC-derived apoptotic bodies. Licensing impacted the uptake of ABs by recipient immune cells and importantly altered their phenotypes. ABs derived from IFN-γ/TGF-β1-licensed apoptotic MSCs significantly inhibited T cell proliferation, induced more regulatory T cells, and maintained immunomodulatory T cells but reduced pro-inflammatory T cells.</description><subject>Apoptotic body</subject><subject>Bone Marrow</subject><subject>Cells, Cultured</subject><subject>Exosomes - metabolism</subject><subject>Extracellular vesicle</subject><subject>Humans</subject><subject>IFN-γ</subject><subject>Immunomodulation</subject><subject>Licensing</subject><subject>Mesenchymal Stem Cells - metabolism</subject><subject>Mesenchymal stromal cells</subject><subject>Potency</subject><subject>TGF-β1</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rHSEUhqWkNGnaf1DKLLOZG3X8uptACW0aCGTTrsXRM8TLqBN1Uu6_r5dJu8zGI_q8Hs-D0BeCdwQTcX3Y-Vh9WHYU02FHCMF78Q5dECVVTyTmZ23Phey5FPtz9LGUA8btnJEP6HyQSpK2XCB_H8IaU0hunU1N-dhNa7TVp9ilqZu9hVjAdU9rMLEbU4QumJzTny5AgWifjsHMXak5naqFee4dZP_SImZJS03V2xZzHson9H4yc4HPr_US_f7x_dftz_7h8e7-9ttDbxlWtacUjMWCs2mcqKB8IFwSQRh17Z7v1Z5hYR0XlFHBRINGyQcpnJEjEZzj4RJdbe8uOT2vUKoOvpx-ZiKktWiqFKFMSqUayjbU5lRKhkkv2bf5jppgfZKsD3qTrE-S9Sa5xb6-dljHAO5_6J_VBtxsALQ5XzxkXaxvtsD5DLZql_zbHf4CKJ6Qow</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Wang, Jiemin</creator><creator>Donohoe, Ellen</creator><creator>Canning, Aoife</creator><creator>Moosavizadeh, Seyedmohammad</creator><creator>Buckley, Fiona</creator><creator>Brennan, Meadhbh Á.</creator><creator>Ryan, Aideen E.</creator><creator>Ritter, Thomas</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6461-8131</orcidid><orcidid>https://orcid.org/0000-0002-5831-6783</orcidid><orcidid>https://orcid.org/0000-0001-7709-8489</orcidid></search><sort><creationdate>202312</creationdate><title>Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies</title><author>Wang, Jiemin ; Donohoe, Ellen ; Canning, Aoife ; Moosavizadeh, Seyedmohammad ; Buckley, Fiona ; Brennan, Meadhbh Á. ; Ryan, Aideen E. ; Ritter, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-22eac0654fbf2625315716142dc405989406cd56242646fbfb75376da7b165503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Apoptotic body</topic><topic>Bone Marrow</topic><topic>Cells, Cultured</topic><topic>Exosomes - metabolism</topic><topic>Extracellular vesicle</topic><topic>Humans</topic><topic>IFN-γ</topic><topic>Immunomodulation</topic><topic>Licensing</topic><topic>Mesenchymal Stem Cells - metabolism</topic><topic>Mesenchymal stromal cells</topic><topic>Potency</topic><topic>TGF-β1</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jiemin</creatorcontrib><creatorcontrib>Donohoe, Ellen</creatorcontrib><creatorcontrib>Canning, Aoife</creatorcontrib><creatorcontrib>Moosavizadeh, Seyedmohammad</creatorcontrib><creatorcontrib>Buckley, Fiona</creatorcontrib><creatorcontrib>Brennan, Meadhbh Á.</creatorcontrib><creatorcontrib>Ryan, Aideen E.</creatorcontrib><creatorcontrib>Ritter, Thomas</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jiemin</au><au>Donohoe, Ellen</au><au>Canning, Aoife</au><au>Moosavizadeh, Seyedmohammad</au><au>Buckley, Fiona</au><au>Brennan, Meadhbh Á.</au><au>Ryan, Aideen E.</au><au>Ritter, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2023-12</date><risdate>2023</risdate><volume>125</volume><issue>Pt A</issue><spage>111096</spage><epage>111096</epage><pages>111096-111096</pages><artnum>111096</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>[Display omitted] •Licensing can enhance the immunomodulatory effect of mesenchymal stromal cells.•Apoptotic bodies derived from mesenchymal stromal cells are immunomodulatory.•The efficacy of apoptotic bodies may be related to their uptake. Mesenchymal stromal cells (MSCs) show great potential for immunomodulatory and anti-inflammatory treatments. Clinical trials have been performed for the treatment of Type 1 diabetes, graft-versus-host disease and organ transplantation, which offer a promise of MSCs as an immunomodulatory therapy. Nevertheless, their unstable efficacy and immunogenicity concerns present challenges to clinical translation. It has emerged that the MSC-derived secretome, which includes secreted proteins, exosomes, apoptotic bodies (ABs) and other macromolecules, may have similar therapeutic effects to parent MSCs. Among all of the components of the MSC-derived secretome, most interest thus far has been garnered by exosomes for their therapeutic potential. However, since MSCs were reported to undergo apoptosis after in vivo transplantation and release ABs, we speculated as to whether ABs have immunomodulatory effects. In this study, cytokine licensing was used to enhance the immunomodulatory potency of MSCs and ABs derived from licensed MSCs in vitro were isolated to explore their immunomodulatory effects as an effective non-viable cell therapy. IFN-γ and IFN-γ/TGF-β1 licensing enhanced the immunomodulatory effect of MSCs on T cell proliferation. Further, TGF-β1 and IFN-γ licensing strengthened the immunomodulatory effect of MSC on reducing the TNF-α and IL-1β expression by M1 macrophage-like THP-1 cells. Additionally, we discovered the immunomodulatory effect mediated by MSC-derived apoptotic bodies. Licensing impacted the uptake of ABs by recipient immune cells and importantly altered their phenotypes. ABs derived from IFN-γ/TGF-β1-licensed apoptotic MSCs significantly inhibited T cell proliferation, induced more regulatory T cells, and maintained immunomodulatory T cells but reduced pro-inflammatory T cells.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37871378</pmid><doi>10.1016/j.intimp.2023.111096</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6461-8131</orcidid><orcidid>https://orcid.org/0000-0002-5831-6783</orcidid><orcidid>https://orcid.org/0000-0001-7709-8489</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2023-12, Vol.125 (Pt A), p.111096-111096, Article 111096
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_2881247788
source MEDLINE; Elsevier ScienceDirect Journals
subjects Apoptotic body
Bone Marrow
Cells, Cultured
Exosomes - metabolism
Extracellular vesicle
Humans
IFN-γ
Immunomodulation
Licensing
Mesenchymal Stem Cells - metabolism
Mesenchymal stromal cells
Potency
TGF-β1
Transforming Growth Factor beta1 - metabolism
title Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunomodulatory%20function%20of%20licensed%20human%20bone%20marrow%20mesenchymal%20stromal%20cell-derived%20apoptotic%20bodies&rft.jtitle=International%20immunopharmacology&rft.au=Wang,%20Jiemin&rft.date=2023-12&rft.volume=125&rft.issue=Pt%20A&rft.spage=111096&rft.epage=111096&rft.pages=111096-111096&rft.artnum=111096&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2023.111096&rft_dat=%3Cproquest_cross%3E2881247788%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2881247788&rft_id=info:pmid/37871378&rft_els_id=S1567576923014224&rfr_iscdi=true